A Single Center, Phase 2B, Randomized, Double Blind, Study to Assess the Efficacy, Safety, and Tolerability of Twice Daily Oral ALLOD-2 vs. Placebo in the Treatment of Chronic Low Back Pain
Not yet recruiting
Phase of Trial: Phase II/III
Latest Information Update: 27 Jul 2017
At a glance
- Drugs ALLOD 2 (Primary)
- Indications Back pain
- Focus Registrational; Therapeutic Use
- Acronyms ANODYNE-4
- Sponsors Allodynic Therapeutics
- 11 Jul 2017 Planned End Date changed from 17 Oct 2018 to 1 Oct 2018.
- 11 Jul 2017 Planned primary completion date changed from 17 Jul 2018 to 1 Jul 2018.
- 11 Jul 2017 Planned initiation date changed from 17 Jul 2017 to 1 Jul 2017.